Driving CARs on the uneven road of antigen heterogeneity in solid tumors.
Driving CARs on the uneven road of antigen heterogeneity in solid tumors.
Curr Opin Immunol. 2018 Mar 16;51:103-110
Authors: Chen N, Li X, Chintala NK, Tano ZE, Adusumilli PS
Abstract
Uniform and strong expression of CD19, a cell surface antigen, on cells of B-cell lineage is unique to hematologic malignancies. Tumor-associated antigen (TAA) targets in solid tumors exhibit heterogeneity with regards to intensity and distribution, posing a challenge for chimeric antigen receptor (CAR) T-cell therapy. Novel CAR designs, such as dual TAA-targeted CARs, tandem CARs, and switchable CARs, in conjunction with inhibitory CARs, are being investigated as means to overcome antigen heterogeneity. In addition to heterogeneity in cancer-cell antigen expression, the key determinants for antitumor responses are CAR expression levels and affinity in T cells. Herein, we review CAR T-cell therapy clinical trials for patients with lung or pancreatic cancers, and provide detailed translational strategies to overcome antigen heterogeneity.
PMID: 29554494 [PubMed - as supplied by publisher]
Source: Current Opinion in Immunology - Category: Allergy & Immunology Authors: Chen N, Li X, Chintala NK, Tano ZE, Adusumilli PS Tags: Curr Opin Immunol Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Clinical Trials | Hematology | Pancreas | Pancreatic Cancer